BHST
BioHarvest Sciences Inc.
BHST offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT
Caterpillar Inc.
CAT has the edge over BHST overall, supported by lower modeled downside and stronger modeled upside.
BHST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
BHST's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
BHST PE Valuation
BHST has no meaningful PE right now: it lost money over the past year.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
BHST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect BHST's losses to shrink, with revenue growing.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
BHST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.54 | +$0.16 |
| Q1 2026 | -$0.62 | -$0.12 |
| Q4 2025 | -$0.63 | +$0.22 |
| Q3 2025 | -$0.68 | +$0.54 |
| Q2 2025 | -$0.70 | +$0.49 |
| Q1 2025 | -$0.50 | +$0.86 |
| Q4 2024 | -$0.85 | +$0.09 |
| Q3 2024 | -$1.22 | -$0.61 |
BHST is still losing money, but far less than before: $0.54 per share over the past year, against $1.36 at its worst in early 2024.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over BHST on earnings quality, reporting a profit while its opponent remains loss making.
BHST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | +3.8% |
| Q1 2026 | $8.5M | +8.2% |
| Q4 2025 | $9.1M | +25% |
| Q3 2025 | $9.1M | +39% |
| Q2 2025 | $8.5M | +41% |
| Q1 2025 | $7.9M | +47% |
| Q4 2024 | $7.3M | +61% |
| Q3 2024 | $6.5M | +102% |
BHST has the edge over CAT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -28% | -7.1 points |
| Q1 2026 | -22% | +0.3 points |
| Q4 2025 | -12% | +11 points |
| Q3 2025 | -10% | +22 points |
| Q2 2025 | -21% | +8.1 points |
| Q1 2025 | -22% | +4.8 points |
| Q4 2024 | -23% | +33 points |
| Q3 2024 | -32% | +30 points |
BHST's operating margin was −28% last quarter, down 7.1 points from the same quarter a year ago.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over BHST on profitability, with a higher operating margin.
BHST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.3M | -$1.2M |
| Q1 2026 | -$2.2M | -$59K |
| Q4 2025 | -$2.9M | +$387.3K |
| Q3 2025 | -$2.5M | -$270.7K |
| Q2 2025 | -$2.1M | +$542.1K |
| Q1 2025 | -$2.1M | -$311K |
| Q4 2024 | -$3.3M | -$126.9K |
| Q3 2024 | -$2.3M | -$836K |
BHST has burned cash in almost every quarter: −$11M over the past year, against −$10M the year before.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over BHST on cash generation, producing positive trailing cash flow while its opponent burns cash.
BHST Net Leverage
BHST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
BHST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 17.3 | Oversold |
BHST's weekly RSI is 33 (neutral) and its Stochastic is 17 (oversold).
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
BHST PE vs Industrials Sector
BHST has no meaningful PE right now: it lost money over the past year.
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
BHST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.63 | 0% above |
| 20 week MA | $1.97 | 17% below |
| 50 week MA | $3.45 | 53% below |
| 100 week MA | $5.30 | 69% below |
CAT has stronger trend alignment. BHST is above 1 of 4 weekly averages versus CAT above 2 of 5.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
BHST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $4.80 | $6.15 | +28% |
| 2025 | $6.15 | $5.33 | -13% |
| 2026 YTD | $5.33 | $1.63 | -69% |
BHST has finished lower in one of the last two years. It's down 69% so far in 2026.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over BHST on returns for 2026, with the stronger performance.